Servier × Owkin
Owkin and Servier announced an agreement for Servier to license Owkin's K Pro AI scientist platform and access its associated multimodal patient data from the MOSAIC network. [71, 72] The collaboration aims to advance Servier's oncology research by using AI to analyze complex patient data and generate hypotheses with greater speed. [73, 77] This deal expands a previous partnership between the two companies that focused on patient subgroup identification. [72]
The asset
A license to the K Pro AI platform and access to multimodal patient data from the MOSAIC network for oncology research. [71, 72, 73]
- 3k total patients in MOSAIC network
The record
- Seller status
- Going concern
- Sector
- AI drug discovery
- Modalities
- text, images, genomic_data
- Jurisdiction
- FR
- Personal data
- The data is sourced from Owkin's federated network, which is designed to enable collaborative research while enhancing data privacy. [98]
What it means if you hold data
This deal exemplifies the growing trend of pharmaceutical companies licensing curated, multimodal patient datasets to power AI-driven drug discovery. It highlights the value of specialized, rights-cleared data in high-stakes research, moving beyond what manual analysis can provide. [71, 77]
Sources
- unite.ai — https://www.unite.ai/owkin-licenses-k-pro-patient-data-to-servier-for-oncology-research/
- contractpharma.com — https://www.contractpharma.com/contents/view_breaking-news/2026-09-11/servier-becomes-latest-company-to-license-owkins-k-pro-ai-scientist/
- pulse2.com — https://pulse2.com/owkin-licenses-k-pro-ai-scientist-and-multimodal-patient-data-to-servier-for-oncology-research/